Lysozyme-containing drug for tear-substitutive pharmaco-therapeutic effectiveness
DOI:
https://doi.org/10.11603/mcch.2410-681X.2018.v0.i2.9146Keywords:
lysozyme, “artificial tear”, traumatic keratitis” anti-inflammatory and regenerative properties.Abstract
Introduction. The prospective method of dry eye syndrome (DES) is the tear-substitutive therapy with the help of eye drops, among which there are absent such with enzyme lysozyme (EC 3.2.1.17), possessing bacteriolytic,
immunostimulating, anti-inflammatory, regenerating, analgetic activity and have the protective function of lacrimal liquid. Because we had developed the preparation with lysozyme, timely for application in such direction and its
ophthalmosafety was shown, the investigation of it’s pharmacotherapeutic effectiveness was advisable.
The aim of the study – investigation of the pharmaco-therapeutic effectiveness of eye drops “artificial tear” with lysozyme as a potential drug for the dry eye syndrome treatment.
Research Methods. The study of the anti-inflammatory and regenerative properties of the produced eye drops with lysozyme was conducted on 6 sexually mature healthy rabbits of the Chinchilla strain with modelled traumatic
keratitis.
Results and Discussion. Basing on the previously obtained experimental data, the stable, highly active, sterile eye drops “artificial tear” with lysozyme were made for their pharmaco-therapeutic effectiveness investigation on the Chinchilla rabbits with modelled traumatic keratitis. It was shown, that instillations of eye drops "artificial tear" with lysozyme in the treatment of traumatic keratitis have an anti-inflammatory and regenerative effect, helping the more quick liquidation of the inflammation and acceleration of the epithelization process compared with control.
Conclusions. For conduction of preclinical research, the highly-active, stable, sterile eye drops “artificial tear” with lysozyme were made. The instillations of the obtained eye drops at treatment of traumatic keratitis renders anti-inflammatory and regenerative effect, helping the more quick liquidation of inflammation and the acceleration of the epithelization process.
References
Brzheskiy, V.V., & Somov, E.E. (2002). Sindrom sukhogo glaza: sovremennye aspekty diagnostiki i lecheniya [Dry eye syndrome: modern aspects of diagnosis and treatment]. Sindrom sukhogo glaza – Dry Eye
Syndrome, (1), 3-9 [in Russian].
Kovalenko, L. (2015). Chto dolzhny znat o sindrome sukhogo glaza vrachi obshchey praktiki [What should doctors of general practices know about the dry eye syndrome]. Neonatolohіia, khіrurhіia ta perynatalna medytsyna
– Neonatology, Surgery and Perinatal Medicine, (4), 126-128 [in Russian].
Bron, A.J. (2015). The definition and classification of dry eye disease. Part of the series Essentials in Ophthalmology, Dry Eye, 1-19.
Dekіna, S.S., Romanovska, І.І., & Sotnіkova, O.P. (2015). Lіzotsyvmіsnyi preparat “shtuchna slioza”: otrymannia, vlastyvosti [Lysozyme-containing drug “artificial tear”: obtaining, properties]. Mіkrobіolohіia і bіotekhnolohіia
– Microbiology and Biotechnology, (4),46-52 [in Ukrainian].
Gorin, G., Wang, S.F., Papapavlou, L. (1971). Assay of lysozyme by its lytic action on M. lysodeikticus cells. Anal. Biochem., 39, (1), 113-127.
Hartree, E.F. (1972). Determination of protein: a modification of the Lowry method, that gives a linear photometric response. Anal. Biochem, 48 (2), 422-427.
Chayka, L.A., Tsipkun, A.G., & Gaydamaka, T.B. (2003). Eksperimentalnoe izuchenie bezvrednosti i farmakologicheskoy aktivnosti glaznykh lekarstvennykh sredstv: metod. rekomendatsii [Experimental study of
harmlessness and pharmacological activity of ophthalmic drugs: methodical recommendations]. Kyiv: Avitsenna [in Russian].
